Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06908356 · ClinicalTrials.gov registry record · Phase 2
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
A Phase 2 study of Focal Onset Seizure and Primary Generalized Epilepsy, sponsored by Praxis Precision Medicines.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 11
- Study locations
NCT06908356: Recruiting Phase 2 study of Focal Onset Seizure and Primary Generalized Epilepsy, sponsored by Praxis Precision Medicines.
NCT06908356 is a Phase 2 study of Focal Onset Seizure and Primary Generalized Epilepsy that is actively recruiting participants, run by Praxis Precision Medicines. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06908356, a Phase 2 study of Focal Onset Seizure and Primary Generalized Epilepsy, is actively recruiting participants, sponsored by Praxis Precision Medicines.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 11
- Study locations
Study Summary
An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures
Primary Outcome
Median percent change in monthly (28 days) seizure frequency from the Screening/Observation Period to the Treatment Period for PRAX-628
Conditions Studied
Interventions
- DRUG 30mg PRAX-628
Study Locations (11)
Other
- Praxis Research Site - Heidelberg
- Praxis Research Site - Melbourne
- Praxis Research Site - Madrid
Texas
- Praxis Research Site - Round Rock
- Praxis Research Site - Seabrook
Arizona
- Praxis Research Site - Phoenix
Florida
- Praxis Research Site - Miami Lakes
Maryland
- Praxis Research Site - Bethesda
Missouri
- Praxis Research Site - Chesterfield
New Jersey
- Praxis Research Site - Hackensack
New York
- Praxis Research Site - Middletown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-01-10 |
| Est. Completion | 2025-07 |
| Phase | Phase 2 |
What NCT06908356 shows while recruiting
NCT06908356 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Focal Onset Seizure appearing as the primary indexed condition, and to 1 intervention - of which 30mg PRAX-628 is the first listed.
NCT06908356 lists 11 locations in 8 states (Other, Texas, Arizona).
Frequently Asked Questions
What is clinical trial NCT06908356 about?
NCT06908356 is a clinical study titled "An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures". An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures
What is the current status of trial NCT06908356?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-01-10. Estimated completion is 2025-07.
What conditions does trial NCT06908356 study?
This clinical trial studies the following conditions: Focal Onset Seizure, Primary Generalized Epilepsy.
What interventions are being tested in trial NCT06908356?
The interventions under investigation include: 30mg PRAX-628 (DRUG).
Who is sponsoring clinical trial NCT06908356?
This trial is sponsored by Praxis Precision Medicines, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06908356 being conducted?
This trial has 11 study locations across Arizona, Florida, Maryland, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Onset Seizure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06908356's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI